Worth reading
78Important
Scored from 2 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
280
¥ millionWording
Conditional
How definitive the wording is.Details of issuance or disposal
Change in the use of funds related to the Series 8 stock acquisition rights issued through a private placement (already issued portion)
Amount of funds to be raised
¥1,074 million in total (¥516 million allocated as of the current date)
Specific use of funds
Repayment of BorrowingsAmount ¥70 million / Scheduled timing of expenditures January 2025
Working capital (personnel expenses, rent and other selling, general and administrative expenses, etc.)Amount ¥318 million / Scheduled timing of expenditures January 2025 to June 2027
Regenerative Medicine-Related BusinessAmount ¥405 million / Scheduled timing of expenditures January 2025 to June 2027
Grid-scale battery storage business (part of the purchase price of the Shokawa Battery Storage Facility)Amount ¥280 million / Scheduled timing of expenditures September 2026
Most recent equity financing
Timing Disclosure dated 15 January 2025 / Type Issuance and exercise of Series 8 stock acquisition rights through a private placement / Amount ¥1,074 million
Impact on Business Performance
The impact on the Company's consolidated financial results for the fiscal year ending December 2026 is currently expected to be minor.
| Item | Details |
|---|---|
| Type of issuance or disposal | Change in the use of funds related to the Series 8 stock acquisition rights issued through a private placement (already issued portion) |
| Amount of funds to be raised | ¥1,074 million in total (¥516 million allocated as of the current date) |
| Specific use of funds | Details Repayment of Borrowings / Amount ¥70 million / Scheduled timing of expenditures January 2025, Details Working capital (personnel expenses, rent and other selling, general and administrative expenses, etc.) / Amount ¥318 million / Scheduled timing of expenditures January 2025 to June 2027, Details Regenerative Medicine-Related Business / Amount ¥405 million / Scheduled timing of expenditures January 2025 to June 2027, Details Grid-scale battery storage business (part of the purchase price of the Shokawa Battery Storage Facility) / Amount ¥280 million / Scheduled timing of expenditures September 2026 |
| Most recent equity financing | Timing Disclosure dated 15 January 2025 / Type Issuance and exercise of Series 8 stock acquisition rights through a private placement / Amount ¥1,074 million |
| Impact on Business Performance | The impact on the Company's consolidated financial results for the fiscal year ending December 2026 is currently expected to be minor. |
Items this document does not state (23)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is because a specific investment opportunity has arisen in the grid-scale battery storage business, and the funds will be used in part to purchase the Shokawa Battery Storage Facility from Recharge Power合同会社. The company said this followed a renewed review of business progress, the business environment, future business development and the allocation of funds.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.